仙琚制药(002332) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥1,173,987,748.45, representing a 0.96% increase year-over-year[3] - Net profit attributable to shareholders was ¥185,187,592.62, up 20.93% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses reached ¥177,760,359.94, reflecting a 21.12% increase year-over-year[3] - Total operating revenue for the current period reached ¥3,317,191,595.25, an increase of 13.1% compared to ¥2,933,659,236.31 in the previous period[24] - Operating profit for the current period was ¥558,228,356.10, up from ¥470,527,145.59, reflecting a growth of 18.6%[24] - Net profit attributable to the parent company was ¥459,227,911.54, compared to ¥358,457,332.81 in the previous period, marking a 28.0% increase[27] - The total comprehensive income for the current period was ¥425,629,559.55, compared to ¥381,646,475.88, an increase of 11.5%[27] - Basic earnings per share for the current period was ¥0.4642, up from ¥0.39 in the previous period, an increase of 18.0%[27] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥6,995,904,196.50, a 2.31% increase from the end of the previous year[3] - The equity attributable to shareholders increased to ¥4,720,174,142.12, marking a 6.19% rise compared to the end of last year[3] - Total liabilities decreased to ¥2,162,369,113.40 from ¥2,255,881,487.04, a reduction of 4.1%[24] - The company’s total liabilities increased by 55.61% for non-current liabilities due within one year, amounting to an increase of ¥162,987,100[6] - Total cash and cash equivalents at the end of the period amounted to 1,213,586,617.63, up from 960,115,539.77 in the previous period, representing an increase of approximately 26.38%[35] Cash Flow - Cash flow from operating activities for the year-to-date was ¥489,272,169.41, showing a 3.69% increase[3] - Cash flow from operating activities was ¥2,883,823,085.02, compared to ¥2,523,286,342.21, indicating a growth of 14.3%[29] - The net cash flow from operating activities was 489,272,169.41, an increase from 471,861,338.07 in the previous period, reflecting a growth of approximately 0.87%[32] - The net cash flow from financing activities was -326,033,822.03, worsening from -114,778,625.43 in the previous period, showing a significant decline[35] Investments and Expenses - The company reported a significant increase in investment income of 224.93%, amounting to an increase of ¥861.57 million[6] - The company experienced a 59.61% decrease in financial expenses, down by ¥26,379,100[6] - Research and development expenses increased to ¥156,896,426.83, up from ¥133,012,662.97, representing an increase of 18.0%[24] - The company reported a decrease in financial expenses to ¥17,870,828.20 from ¥44,249,974.84, a reduction of 59.7%[24] Shareholder Information - Total number of common shareholders at the end of the reporting period was 37,000[10] - The largest shareholder, Xianju County State-owned Assets Investment Group Co., Ltd., holds 21.55% of shares, totaling 213,221,808 shares[10] Other Financial Metrics - The company reported a decrease in goodwill from ¥619,766,791.91 to ¥581,128,869.67[16] - Cash paid for purchasing goods and services was 671,448,016.59, an increase from 605,876,000.95, indicating a rise of approximately 10.5%[32] - Cash paid for employee compensation was 485,054,008.61, compared to 433,743,398.36 in the previous period, marking an increase of about 11.8%[32] - Cash outflow from investment activities totaled 176,802,076.94, up from 126,709,134.42, indicating an increase of approximately 39.5%[32] - The company reported cash received from other operating activities of 100,327,144.54, down from 173,327,482.32, reflecting a decrease of about 42.2%[32]